Biomarkers and outcomes in checkpoint inhibitor-associated diabetes and hyperglycemia
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.